<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28395">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737072</url>
  </required_header>
  <id_info>
    <org_study_id>16387</org_study_id>
    <secondary_id>I2V-MC-CXAD</secondary_id>
    <nct_id>NCT02737072</nct_id>
  </id_info>
  <brief_title>A Study of LY2510924 and Durvalumab in Participants With Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination With the Anti-PD-L1 Antibody, Durvalumab (MEDI4736), in Advanced Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of chemokine
      (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a
      and 1b in participants with advanced refractory solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (28 Days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of LY2510924</measure>
    <time_frame>Cycle 1 (28 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC0-24) of LY2510924 when Co-Administered with Durvalumab</measure>
    <time_frame>Predose Cycle 1 Day 1 through 90 Day Post Treatment Follow Up (Estimated up to 9 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Durvalumab Antibodies when Administered in Combination with LY2510924</measure>
    <time_frame>Predose Cycle 1 Day 1 through 90 Day Post Treatment Follow Up (Estimated up to 9 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Proportion of Participants Who Exhibit Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Measured Progressive Disease or Death (Estimated up to 18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Proportion of Participants who Exhibit Stable Disease (SD), CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 18 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>LY2510924 + Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2510924 given subcutaneously (SQ) in combination with durvalumab given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2510924 + Durvalumab (Expansion 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2510924 given SQ in combination with durvalumab given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2510924 + Durvalumab (Expansion 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2510924 given SQ in combination with durvalumab given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2510924</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>LY2510924 + Durvalumab</arm_group_label>
    <arm_group_label>LY2510924 + Durvalumab (Expansion 1)</arm_group_label>
    <arm_group_label>LY2510924 + Durvalumab (Expansion 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY2510924 + Durvalumab</arm_group_label>
    <arm_group_label>LY2510924 + Durvalumab (Expansion 1)</arm_group_label>
    <arm_group_label>LY2510924 + Durvalumab (Expansion 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phase 1a: Have histologic or cytologic confirmation of advanced solid tumor

          -  Have at least 1 measurable lesion assessable using standard techniques by Response
             Evaluation Criteria in Solid Tumours (RECIST) v1.1

          -  Have adequate organ function

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale

          -  Have provided tissue from a newly obtained core or excisional biopsy of a tumor
             lesion or a recent biopsy defined by ≤3 years since last documented progression of
             disease

          -  Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator

        Exclusion Criteria:

          -  Have a serious concomitant systemic disorder including human immunodeficiency virus
             (HIV), active hepatitis B virus (HBV), active HCV, active autoimmune disorder or
             disease requiring high dose of steroids

               -  Have a bowel obstruction, history or presence of inflammatory enteropathy or
                  extensive intestinal resection or chronic diarrhea

               -  Have evidence of interstitial lung disease that is symptomatic or may interfere
                  with the detection or management of suspected drug-related pulmonary toxicity or
                  active, noninfectious pneumonitis

               -  Have an active infection requiring systemic therapy

          -  Have had prior therapy with an anti-programmed cell death 1 (PD-1), anti-PD-L1,
             anti-PD-L2, or anticytotoxic T lymphocyte-associated antigen-4 antibody

          -  Moderate or severe cardiovascular disease

          -  Have symptomatic or uncontrolled brain metastases, spinal cord compression, or
             leptomeningeal disease requiring concurrent treatment

          -  Have received a live vaccine within 30 days before the first dose of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiples sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>303-724-3851</phone>
    </contact>
    <investigator>
      <last_name>Colin Weekes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>773-702-0360</phone>
    </contact>
    <investigator>
      <last_name>Hedy Kindler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-362-7229</phone>
    </contact>
    <investigator>
      <last_name>Andrea Wang-Gilliam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-360-0919</phone>
    </contact>
    <investigator>
      <last_name>Mark O'Hara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/solid-tumor/CXAD#?postal=</url>
    <description>Click here for more information about this study: A Study of LY2510924 and Durvalumab in Participants With Solid Tumors</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>April 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immuno-oncology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
